. More interestingly, a substantial amount of data have emerged showing that locally applied radiation can also stimulate systemic immune responses to adaptive immunity 7, 8 . Several other mechanisms of tumour sensitization following radiotherapy, including increased expression of cytokines and modulation of tumour phenotypes, have also been associated with promising outcomes [9] [10] [11] (FIG. 1) . Termed 'immunogenic modulation' , these processes encompass a spectrum of radiation-induced molecular alterations in the biology of the cancer cell that, either independently or collectively, make the tumour more amenable to cytotoxic-T-lymphocytemediated destruction. These mechanisms have been reviewed in detail elsewhere 12 , and include the following: downregulation of antiapoptotic and/or prosurvival genes 13, 14 ; modulation of antigen-processing machinery components 15, 16 ; and translocation of calreticulin to the cell surface of the tumour 12, 15 . These radiation-induced changes can be exploited to provide synergistic clinical benefits when the radiation treatment is followed by, or given concurrently with, an immunotherapy regimen.
Technological advances that enable the delivery of higher doses of localized radiation to tumour targets with stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), have been widely implemented in curing patients with early stage cancers of the lung and liver, and its role as a treatment of patients with metastatic disease is being actively investigated [17] [18] [19] . SABR involves treatment of tumours with radiation doses that often exceed 5 Gy per fraction with an exceedingly high level of conformity and sharp dose fall-off to spare the surrounding organs at risk. Investigators in many previous studies have focused on the effects of conventional fractionation regimens on the immune system; however, preliminary data suggest that radiation-induced immune responses might be dose-dependent 20, 21 . In fact, using radiation doses in the 'ablative' range can not only effectively destroy tumour cells directly, but might also encourage these SABR-killed cells to function as an antitumour vaccine in situ 22, 23 . Herein, we provide a definitive description of ISABR (immunotherapy and SABR used concurrently or subsequently), whereby exposure of tumour cells to higher doses of radiation delivered in a responses, thus leading to enhanced tumour cell recognition by the immune system and death of the tumour cells (FIG. 1) . A number of investigators have reported that, following irradiation, tumour cells release a large amount of antigens, referred to as tumourassociated antigens (TAAs), in the form of necrotic and apoptotic tumour cells and debris [3] [4] [5] . This substantial increase in the number and diversity of TAAs can enable antigen-presenting cells and dendritic cells to stimulate a tumour-specific immune response (FIG. 1) . In addition to tumour cells acting as the trigger, the destruction of the tumour-supporting stroma that often results from radiotherapy can also potentiate immune recognition 6 . Other reports have focused on the release of 'danger' signals following radiotherapy, which might promote the transition from nonspecific immune 
Immunogenic modulation limited number of fractions promotes productive interactions between tumours and the immune system, which can be further exploited and/or augmented using active immunotherapy Following cell death, the release of tumour debris with associated danger signals, tumour-associated antigens (TAAs), and inflammatory cytokines are recognized by and activate dendritic cells, promoting antigen presentation to cells of the immune system. Polyclonal antigen-specific T cells are then generated, some of which can attack tumours located within the radiation field, as well as distant tumours; this response can be augmented by the addition of systemic immune-enhancement measures. CTLA-4, cytotoxic-T-lymphocyte-associated antigen 4; DAMP, damage-associated molecular pattern; GITR, glucocorticoid-induced tumour-necrosis-factor receptor family related gene; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; MHC, major histocompatibility complex; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3.
OVA-expressing B16-F0 tumours with single (15 Gy) or fractionated (3 Gy × 5 fractions) doses of radiation 25 . Use of either fractionation schedule facilitated antigen presentation and priming of T cells in draining lymph nodes. Once primed, these tumour-antigen-specific T cells had an enhanced ability to traffic to and infiltrate tumours. Both regimens were successful in stimulating the immune system, although use of 15 Gy single-dose irradiation resulted in a greater number of host immune cells infiltrating tumours, compared with the 3 Gy × 5 fractionated schedule 25 . This important difference in the immune response following irradiation with varying radiation fraction sizes was further highlighted elsewhere 21 : Mice bearing B16-OVA murine melanoma were treated with up to 15 Gy radiation in various fraction sizes, and tumour growth followed. Researchers showed effective immune stimulation with radiation doses of 7.5 Gy and 10 Gy, but not 5 Gy. Conversely, use of higher doses of radiation, namely ≥15 Gy, increased the fraction of splenic regulatory T (T REG ) cells, which function to suppress tumour-specific addition of immunotherapeutic treatments, we analysed changes in tumour phenotypes at several time points following SABR. Whereas increased expression of immunostimulatory markers, including OX-40 ligand and 41BB ligand, was evident 72 hours after SABR, decreased expression of PD-L1 (programmed cell death 1 ligand 1), an inhibitor of T-cell expansion and function 28 , for example, was detected up to 144 hours after SABR 20 . These studies focused on the immunomodulatory effects of SABR; however, the successful combination of SABR with immunotherapy regimens, resulting in synergistic antitumour effects, has also been reported in the preclinical setting. Cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), similar to PD-L1, functions to inhibit T-cell activation and suppress antitumour immune responses 29 .
Both of these molecules have prominent roles in immune-checkpoint pathways that, when active, maintain self-tolerance and inhibit autoimmune reactions. Data now confirm that many tumours activate certain immune-checkpoint pathways to evade the host immune response and promote resistance. Thus, the development of checkpoint inhibitors has emerged as a prominent treatment strategy that enables stimulation of antitumour immune responses
. Data from an elegant study 30 demonstrated regression of the primary irradiated tumour and distant metastases following radiotherapy (two fractions of 12 Gy) combined with CTLA-4 blockade. Not surprisingly, the substantially improved local and distant tumour control translated into longer durations of overall survival. Further analyses confirmed that these effects were elicited by CD8 + T-celldependent antitumour immunity 30 . Data from a similar study by the same group demonstrated that the use of different SABR regimens (20 Gy × 1, 8 Gy × 3, or 6 Gy × 5) in combination with anti-CTLA-4 antibody therapy again resulted in enhanced or complete regression of the primary tumour compared with use of single-modality therapy. Interestingly, substantial inhibition of tumour growth outside of the radiation field was seen only when immunotherapy was added to the fractionated SABR schedule and not the single-dose regimen 31 .
As seen in a previous study from the same research group, the amount of CD8 + T cells demonstrating tumour-specific IFNγ production was proportional to the inhibition of the secondary tumour. Lastly, in the previously mentioned report 24 , investigators demonstrated that ablative immunity 26 . The importance of the radiation dose and fractionation schedule used was further corroborated in a study showing activation of immune-response-related genes, radiation-induced damage-associated molecular pattern molecules (DAMPs), and inflammatory cytokines in human prostate cancer cells when exposed to radiation in the range of 8-10 Gy
27
. Thus, these data suggest the existence of a threshold dose below which immune stimulation might be suboptimal and above which immunosuppression prevails. Lastly, data from a study by our group, published in 2014 (REF. 20 ), further support not only the importance of fraction size with regards to activation of the immune system, but also the longevity of the immune response following irradiation. We analysed changes in tumour-cell phenotype in prostate cancer cell lines following single-fraction SABR and found that co-stimulatory and co-inhibitory T-cell signalling molecules can be modulated to promote productive antitumour immune responses following treatment with at least 10 Gy doses of radiation. In an attempt to find a potential therapeutic window for the radiotherapy (15-25 Gy × 1) alone generated robust CD8 + T-cell-dependent immunity, leading to reductions in tumour burden, reduced relapse of the primary tumour, and eradication of metastases. These investigators further showed that treatment combining two consecutive 12 Gy doses of radiation with ad-LIGHT, an immunotherapeutic agent and member of the tumour necrosis factor superfamily -composed of a ligand of the stromal-cell-expressed lymphotoxin-β receptor and T-cell-expressed herpes viral entry mediator -resulted in prolonged survival compared with treatment with either modality alone 24 . Treatment with other types of immunotherapy has also been shown to augment antitumour responses when combined with high-dose radiotherapy. Combinations of clinically relevant monoclonal antibodies designed to stimulate antitumour immunity (such as anti-CD137 and anti-CD40 antibodies) or relieve immunosuppression (anti-PD-1 antibodies) with single (12 Gy) or fractionated (4-5 Gy × 4) radiotherapy have also been investigated 32 . Single-fraction treatment combined with anti-CD137 and anti-PD-1 therapy was found to result in enhanced host immune responsiveness to tumours, with a tumour rejection rate of up to 40% in mouse models 32 . Similarly, the fractionated radiotherapy regimens in combination with anti-CD137 and/or anti-PD-1 antibodies were more effective in controlling tumour growth than either treatment alone. Notably, radiotherapy did not deplete, but rather enriched tumours for functionally active, tumour-specific immune effector cells 32 . Data from another study, with results published in 2015 (REF. 33 ), corroborated these observations that perhaps combining immunotherapy techniques that have different mechanisms of action might yield better outcomes. In this study 33 , despite an initial tumour response, resistance was common when radiation was combined with anti-CTLA-4 antibodies. Resistance correlated with upregulation of PD-L1 and T-cell exhaustion; however, the addition of PD-L1 blockade to this regimen reversed T-cell exhaustion, and, as also promoted by anti-CTLA-4, further improved the CD8 + T cell: T REG cell ratio, and further enhanced expansion of the T-cell population and diversification of the T-cell-receptor repertoire 33 . Lastly, treatment with single fractions of 10 Gy radiation in combination with L19-IL-2, a fusion protein designed to selectively deliver IL-2 to cancer cells, targeting tumour neovascularization, compared with 19.9 months in patients who received SRS and ipilimumab therapy. Both treatment with the combination of ipilimumab and SRS were significant predictors of improved overall survival (HR 0.43 and HR 0.45; P = 0.005 and P = 0.008, respectively) 39 . These findings were corroborated in another case report describing a patient with metastatic melanoma, in whom a systemic complete response in the skin and lymph nodes was observed following treatment with ipilimumab and SRS for brain metastases 40 . Additional studies investigating the combination of immunotherapies with SABR, with similar findings to those studies discussed in this section, have also been published [41] [42] [43] [44] (TABLE 1) .
These remarkable results have set the stage for the initiation of several clinical trials investigating the combination of SABR with immunotherapy. Currently, investigators at Johns Hopkins University are enrolling patients with metastatic melanoma with newly diagnosed metastases to the brain or spine; patients will receive an intravenous dose of ipilimumab, followed by CyberKnife® (Accuray Ltd, California, USA) SABR a week later, and three more doses of ipilimumab, to test the safety of this combination 45 . A similar trial, named RADVAX and led by investigators at the Abramson Cancer Center at the University of Pennsylvania, is a stratified phase I/II dose-escalation trial designed to investigate SABR followed by ipilimumab, also in patients with previously treated or untreated metastatic melanoma 46 . A phase I/II trial at the MD Anderson Cancer Center, to which participants are currently being recruited, is designed to investigate the safety and efficacy of the combination of ipilimumab and SABR in patients with advanced-stage solid tumours. Patients will be randomly assigned to receive either concurrent (early) SABR starting on day 1 of ipilimumab therapy, or sequential (late) SABR beginning on day 29 (REF. 47 ). Patients with metastatic cancer and at least one metastatic or primary lesion in the liver, lung or adrenal gland are eligible for enrolment, and a range of other clinical studies in this area are currently published or ongoing 48 (TABLES 1,2). Results of the ongoing trials we have described, which are anticipated to become available in the next few years, will hopefully provide further insight into the appropriate selection of patients that will benefit from ISABR. Until then, the information in the subsequent section might provide some guiding principles for future investigations.
resulted in 75% cure rates and increased the percentage of antigen-specific, CD8 + cytotoxic T cells 34 . Taken together, these data demonstrate not only that effective immune stimulation can be achieved following SABR monotherapy, but also that addition of immunotherapeutic strategies to SABR therapy results in improved outcomes compared with treatment with either modality alone. These promising preclinical results served as the basis for testing this combination in the clinical setting.
Clinical evidence for ISABR
The most well-known success story of combining SABR with immunotherapy was detailed in a case report published in 2012 (REF. 35 ). In conjunction with ipilimumab, an anti-CTLA-4 monoclonal antibody, SABR (28.5 Gy delivered in three fractions) was successfully used to treat a painful metastatic paraspinal lesion in a patient suffering from metastatic melanoma. The findings of post-SABR CT scans confirmed not only a local response, but also substantial regression of distant lesions located outside of the radiation field 35 . Local radiation in combination with anti CTLA-4 immunotherapy resulted in systemic antitumor activity, termed the 'abscopal effect' (REF. 36 ), which seemed to be mediated by the immune system 35 . In a similar case study, authors reported clinically significant improvements in the outcome of a patient with metastatic melanoma. Following SABR (54 Gy in three fractions) treatment of two of seven metastatic liver lesions, a complete systemic response occurred, despite disease progression on ipilimumab alone 37 . A third case report of an abscopal effect of ipilimumab in a patient with metastatic, non-small-cell lung cancer (NSCLC) was published in 2013 (REF. 38 ). While undergoing ipilimumab immunotherapy, the most metabolically-active liver metastatic lesion was selected as the target for SABR and was treated with a total radiation dose of 30 Gy in five fractions. Post-treatment scans showed an objective response within the radiation field as well as resolution of non-irradiated foci in the liver, bone and lung 38 . Lastly, in an intriguing retrospective study with results published in 2013 (REF. 39 ), investigators analysed clinical and radiographic records of patients with melanoma who were treated with ipilimumab and either whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) for brain metastases. The median survival of patients who received WBRT and ipilimumab was 3.1 months
Future directions
On the basis of the preclinical and clinical data presented in this Perspectives, sufficient evidence exists to support continued exploration of the combination of immunotherapy and SABR. Nevertheless, several considerations need to be adequately addressed before the development of a clinical trial designed to test the efficacy of ISABR.
Firstly, appropriate patient selection remains of paramount importance. In nearly all clinical scenarios, factors including tumour site, stage and type will all affect any relevant outcomes. Currently, SABR is most frequently used in the setting of metastatic disease and in patients with stage I NSCLC. Findings of randomized trials have confirmed that for patients with stage I NSCLC, SABR alone results in ≥95% local tumour control within the irradiated field 49, 50 . The rates of microscopic or distant spread in the early stage disease scenario are low: about 5-10% of patients will develop regional lymph-node recurrences, and up to 15% will have distant metastases 51 . SABR only targets primary lesions, although rates of lymph-node recurrence and distant failures are immunotherapy to SABR might further reduce lymph-node involvement and distant disease, potentially leading to even higher cure rates.
In addition to the current patient groups, patients with advanced-stage disease might also achieve important clinical benefits from treatment with ISABR. Patients suffering from oligometastatic disease or those with locally advanced tumours that have a high propensity for metastasis frequently harbour disease that is not routinely detected during laboratory examinations or imaging work-up. Thus, inciting an immune response using a combination of SABR and an immunotherapeutic approach can address the visible disease burden and also target cancer cells that have, thus far, evaded detection using traditional diagnostic approaches. Building upon findings of basic research 34 , a clinical trial is currently ongoing, with the aim of investigating the effectiveness of combining high-dose radiotherapy and the L19-IL-2 fusion protein in patients with oligometastatic solid tumours 56 . In these clinical situations, it remains unclear whether all of the disease needs to be treated, or if SABR targeting just a fraction of the index lesion being treated can nevertheless incite an effective systemic immune response against all oligometastases.
Similarly, patients with a more substantial disease burden might also benefit from ISABR using the same approach. An accessible metastatic lesion targeted with SABR can initiate an immune response, thereby enabling an effective immune-based attack on other metastases located outside of the radiation field. In this scenario, the SABR-treated lesion acts as an in situ tumour vaccine. However, the subsequent immune response following radiation alone is often insufficient to address the distant macroscopic or microscopic disease burden. Additionally, patients with advanced-stage or metastatic disease are frequently treated with several systemic agents, most of which are immunosuppressive. In these instances, in which chemotherapy is used to combat oligometastatic and/or occult metastatic disease, an unanswered question exists concerning whether the use of upfront chemotherapy reduces the recruitment of effector T cells for activation within the irradiated tumour microenvironment -where antigen elaboration occurs. Thus, implementation of an immunotherapeutic strategy, in addition to SABR, might generate a more robust and effective immune response. ISABR relies on the SABR-treated tumour to stimulate a personalized, tumour-specific immune comparable to those seen following surgical resection of the affected lobe and regional lymph-node dissection. Despite the previous assumption that removal of the visible tumour burden in the lung and dissection of draining lymph nodes would result in lower incidences of regional and distant metastases, this theory has not held true based on results of phase II prospective studies 52 , randomized studies 53 and patient-population studies 54 . Furthermore, in a phase III trial, treatment with an antigen-specific immunotherapeutic vaccine, termed MAGE-A3, did not result in any benefit compared with placebo for patients with resected stage IB, II, and IIIA NSCLC, thus failing to meet the primary outcome 55 . One can hypothesize, on the basis of these observations, that the combination of this tumour-specific therapeutic vaccine with SABR might result in the generation of the aforementioned in situ vaccine with subsequent stimulation of an effective systemic immune response (TABLE 2) . Collectively, these findings suggest that localized SABR alone might stimulate the immune system to prevent tumour recurrence and/or metastases. Adding active response; therefore, choosing patients with the most appropriate tumour histology, location, and stage might have a less important role in clinical trials investigating this approach. The optimal timing of the two ISABR treatment modalities is a second important aspect that needs addressing before a trial is embarked upon. Some investigators have proposed that immunotherapeutic treatments should be administered after radiotherapy. One theory hypothesizes that the activation of an immune response and augmentation of this response by immunotherapy might be less effective if radiation has not already generated de novo tumour antigens and broken any pre-existing peripheral immune tolerance of the tumour 57 . Additionally, treatment with SABR following the activation of immune cells could be detrimental to an effective antitumour cellular response, owing to the cytotoxic and ablative nature of this radiotherapy technique 57 . Conversely, administration of SABR after immunotherapy does offer certain advantages: stimulating antigen-presenting cells and effector T cells before SABR will allow these cells to be readily available to respond to the efflux of tumour antigens generated as a result of radiation treatment; similarly, having an active immunoadjuvant within the tumour microenvironment at the time of SABR could maximize its therapeutic effects 57 . Despite these general principles, the immunotherapy agent of choice most probably dictates the optimal sequencing of SABR. For instance, in the example of adoptive T-cell transfer immunotherapy, SABR as the latter therapy would, presumably, interfere with the immune response at the tumour site. Therapeutic cancer vaccine therapy, on the other hand, might require SABR in order to release tumour antigens, which are necessary for activation of antigen presentation and immune-mediated cell killing. To help shed further light on this issue, in a study with results published in abstract form in 2014, investigators administered an anti-CTLA-4 antibody or OX40 agonist antibody either before or after a single radiation dose of 20 Gy to subcutaneous colorectal adenocarcinomas in a mouse model 58 . SABR delivered to the altered tumour microenvironment created by anti-CTLA-4 antibody administration resulted in 100% tumour clearance as opposed to only 50% clearance when an anti-CTLA-4 antibody was sequenced after radiotherapy. Consistent with the notion that the optimal timing of treatment modalities might be determined by the immunotherapy also harbouring tumour cells in other locations, which are undetectable using traditional methods, might derive the greatest clinical benefit from ISABR. Thus, measuring responses to treatment using standard laboratory tests or imaging modalities might falsely reveal a lack of systemic disease control. Sole use of traditional clinical end points, such as tumour resectability, tumour response, disease-free survival, and/or overall survival to assess the efficacy of ISABR might not provide an accurate indication of effectiveness. Therefore, supplementing these more traditional end points with immunological readouts in order to capture an earlier indication of a disease response is recommended, as they can establish proof-of-principle of activation of the immune system before exploration of clinical end points. For instance, measuring the production of inflammatory cytokines in a patient's serum following administration of ISABR might act as an early surrogate for agent selected, administration of the OX40 agonist antibody increased the numbers of activated CD8 + T cells and was optimal when delivered one day after single-fraction radiotherapy 58 . Collectively, taking into account the different specific mechanisms of action of immunotherapeutic strategies might help to dictate the most-appropriate timing of immunotherapeutic interventions in relation to SABR. Thus, these data suggest than an umbrella recommendation regarding the optimal sequencing of immunotherapy and SABR might be misleading, and possibly inappropriate. Rather, obtaining a solid understanding of the mechanism of action of the chosen agent and its role in either stimulating or suppressing a tumour-directed immune response will be more valuable.
A final point, which also requires consideration, is the ability to identify patients' responses to therapy. As mentioned above, patients with obvious progressive disease in a single location, yet potentially . Indeed, tumour mutational load, described as the predicted burden of deleterious alleles 60 , has been demonstrated to positively correlate with an improved objective response, durable clinical benefit and progressionfree survival in patients with NSCLC who received treatment with anti-PD-1 therapy 61 . Lastly, reports published in 2014 (REF. 62) indicate that CTLA-4 inhibition induces evolution and diversification of the T-cell repertoire, thereby increasing the number of unique T-cell-receptor clonotypes. In this study, improved clinical outcomes were associated with less clonotype loss and maintenance of high-frequency clonotypes during treatment 62 ; perhaps these features could act as surrogates for clinically-relevant antitumour responses. In fact, these changes investigators have shown that this bimodal therapeutic approach is not only feasible, but also effective, and that the doses of radiation required fall within the window of conventional fractionation schedules. Within the past two decades, clinicians have taken advantage of technological breakthroughs that enable treatment with higher doses of radiation while maintaining acceptable levels of exposure of the surrounding organs at risk. The popularity of SABR has risen drastically over the past few years and its full potential, no doubt, remains to be realized. Owing to the local efficacy and ablative qualities of SABR as a single modality, SABR is infrequently combined with other treatments, especially immunotherapy. Thus, the goal of this Perspectives was to present the relevant literature supporting the combination of immunotherapy with SABR, described as 'ISABR' , in the preclinical and clinical settings. Currently, a few clinical trials of this approach are underway, although the results are not expected to become available for several years. The aim of the final section of this Perspectives was, therefore, to provide some general guiding principles to consider regarding the development of, and to promote interest in future research efforts, as we believe the synergistic relationship between SABR and immunotherapy is just beginning to blossom. in T-cell clonality have been associated with increased overall survival in clinical trials with cohorts of patients with prostate 63 or breast 64 cancer. These, along with other immunological tests, should be used to supplement standard examination criteria in order to more accurately determine the extent of disease response 65 . Data from another study 66 highlight the challenges in choosing the most-appropriate readouts in clinical immunotherapy studies. The investigators reported tumour progression despite induction of very high levels of tumourantigen-specific CD8 + T cells in patients with melanoma, following vaccination with altered peptide immunogens 66 . Efforts to identify such immune biomarkers in addition to the use of more-traditional measures of disease response should be undertaken so that rational treatment combinations can be designed in terms of intensity, sequencing and maintenance of immune stimulation after combination with SABR. This approach will also enable the possibility of enriching treatment populations in clinical trials with patients who are most likely to respond to treatment and/or tailoring therapy specifically for distinct subsets of patients (TABLE 3) .
Conclusions
The proposal to combine immunotherapy and radiotherapy is not novel. Many .
